Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Mark Mirabelli

Sports Medicine Rochester, NY Medical Doctor

NPI 1518054949 CMS profile 22722

601 Elmwood Ave, Box 665, Rochester, NY 14642

Open in the dashboard

General payments

$178

4 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Mark Mirabelli of Rochester, NY is reported in the CMS Open Payments database as having received $178 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 7th percentile of Sports Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $57 1
2023 General $49 1
2019 General $72 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Mirabelli
  • Sports Medicine median
  • Middle half of Sports Medicine
  • National median

In program year 2025, general payments to Mark Mirabelli were reported at $0. Among 2,404 Sports Medicine profiles paid that year, the median was $664 and the middle half received between $172 and $3,055.

Show as a table
Year Mark Mirabelli Sports Medicine median Middle half National median
2019 $72 $1,176 $199–$4,249 $163
2020 $0 $708 $96–$2,890 $114
2021 $0 $1,213 $152–$3,994 $132
2022 $0 $1,230 $159–$3,998 $149
2023 $49 $584 $146–$2,836 $160
2024 $57 $628 $163–$3,168 $164
2025 $0 $664 $172–$3,055 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Flexion Therapeutics, Inc. $72 2 payments
  2. Philips Electronics North America Corporation $57 1 payment
  3. HydroCision, Inc. $49 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $128 3 payments
  2. Honoraria $50 1 payment
Products named General payments · program years 2019–2024
  1. Zilretta $72 2 payments
  2. (8666) 5500 Series Ultrasound System $57 1 payment
  3. TENJET $49 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

645

Median for Family Practice: 1,826

Drug cost

$29,708

Median for Family Practice: $120,094

Branded share of claims

11.5%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 14 $12,584
Farxiga Dapagliflozin Propanediol Brand 11 $6,016
Diclofenac Sodium Generic 36 $2,113
Omeprazole Generic 34 $1,525
Testosterone Generic 14 $1,106
Albuterol Sulfate Hfa Albuterol Sulfate Brand 31 $984
Atorvastatin Calcium Generic 61 $553
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 18 $550
Duloxetine Hcl Generic 19 $460
Methadone Hcl Generic 11 $384

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$62,521

Of which drugs: $27,180

Medicare patients

205

Average age 68

Services billed

2,506

120 women, 85 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 74%
High blood pressure 70%
Depression 32%
Diabetes 26%
Chronic kidney disease 26%
Ischemic heart disease 20%
Atrial fibrillation 19%
Cancer 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, monovisc, for intra-articular injection, per dose J7327 Office 16 28 $15,011
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 13 1,008 $7,110
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 71 514 $2,780

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Sports Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record